Risk factors

Heavy reliance on Title IV federal student financial aid programs and strict Department of Education compliance rules dominates the risk profile.

TPG Mortgage Investment Trust relies heavily on its manager to source residential mortgage loans and execute securitizations. The company employs significant leverage through master repurchase agreements and corporate debt to finance its mortgage portfolio. Acquisitions like WMC introduce commercial real estate and additional integration risks.

Niagen Bioscience faces concentration risk from Tru Niagen and reliance on wellness and IV therapy market trends. The company depends heavily on third-party contract manufacturers, outsourcing facilities, and key personnel. Extensive government regulations across dietary supplements and pharmaceuticals significantly impact operations.

Commercializing the RNS System relies on Level 4 CEC adoption and specialized neurosurgeon and epileptologist training.

OFS Capital Corp faces heavy risks from relying on OFS Advisor for senior management and deal flow. The company uses leverage, including debt and preferred stock, which magnifies investment losses. Tax compliance as a RIC and asset coverage requirements dictate financial flexibility.

Passage Bio faces typical pre-revenue biotech risks dominated by its sole clinical candidate PBFT02 and novel gene therapy technology. Reliance on third-party manufacturers like Catalent and licensors like Penn creates significant operational dependencies. Intellectual property protection and raising additional capital are critical to future survival.

Customer concentration is high, with one customer accounting for 18 percent of net sales in 2024.

QXO relies heavily on CEO Brad Jacobs to execute an acquisition strategy in the fragmented building products distribution sector. Future growth depends on raising substantial equity and debt financing, which risks significant dilution. The company also maintains a legacy software business facing competitive and technological obsolescence risks.

Rigel faces intense pharmaceutical competition, patent challenges for TAVALISSE, and capital dilution risks. The company relies heavily on third-party distributors and collaborative partnerships for pipeline expansion. Strict regulatory compliance, pricing pressures, and future funding needs dominate the operational landscape.

Ranger Energy Services faces risks tied to E&P capital spending, commodity price volatility, and intense labor and market competition.

RIC tax and distribution requirements constrain cash management and may create tax liabilities.

Southland Holdings faces severe risks from competitive bidding pressures, government contract reliance, project delays, and complex cost estimates.